

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

KATO III

RRID:CVCL_0371

Type: Cell Line

Proper Citation

RRID:CVCL_0371

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0371

Proper Citation: RRID:CVCL_0371

Description: Cell line KATO III is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Down syndrome

Defining Citation: [PMID:209229](#), [PMID:1370612](#), [PMID:1778766](#), [PMID:1933850](#), [PMID:3518877](#), [PMID:3962675](#), [PMID:6862145](#), [PMID:9023415](#), [PMID:9247707](#), [PMID:9290701](#), [PMID:11107048](#), [PMID:11314020](#), [PMID:15723654](#), [PMID:17505008](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24587255](#), [PMID:24807215](#), [PMID:25343454](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29435981](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32028591](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KATO III

Synonyms: Kato III, Kato-III, KATO-III, KATOIII, KatolIII, KATO 3, JTC-28, Japanese Tissue Culture-28

Cross References: BTO:BTO_0001092, CLO:CLO_0007073, CLO:CLO_0050790, EFO:EFO_0002217, MCCL:MCC:0000266, CLDB:cl3000, CLDB:cl5214, AddexBio:C0023001/53, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-103, BCRC:60200, BCRJ:0318, BioGRID_ORCS_Cell_line:909, BioSample:SAMN01821574, BioSample:SAMN01821690, BioSample:SAMN03471089, BioSample:SAMN03473264, BioSample:SAMN10988331, cancercellines:CVCL_0371, CCRID:3101HUMSCSP573, CCRID:3101HUMTCHu229, CCTCC:GDC0253, Cell_Model_Passport:SIDM00687, CGH-DB:122-1, CGH-DB:9024-4, ChEMBL-Cells:ChEMBL3308432, ChEMBL-Targets:ChEMBL612700, CLS:300381, Cosmic:685595, Cosmic:687555, Cosmic:755614, Cosmic:801336, Cosmic:848150, Cosmic:848375, Cosmic:877044, Cosmic:887248, Cosmic:888823, Cosmic:889107, Cosmic:907276, Cosmic:922690, Cosmic:926118, Cosmic:968350, Cosmic:1001657, Cosmic:1067210, Cosmic:1090464, Cosmic:1093302, Cosmic:1187279, Cosmic:1223583, Cosmic:1518254, Cosmic:1571766, Cosmic:1627262, Cosmic:1890472, Cosmic:2009529, Cosmic:2036664, Cosmic:2069771, Cosmic:2484964, Cosmic:2807629, Cosmic:2823224, Cosmic-CLP:907276, DepMap:ACH-000793, ECACC:86093004, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10436-106E4, GDSC:907276, GEO:GSM267419, GEO:GSM267426, GEO:GSM267433, GEO:GSM267440, GEO:GSM552362, GEO:GSM562404, GEO:GSM827547, GEO:GSM828835, GEO:GSM844573, GEO:GSM887200, GEO:GSM888273, GEO:GSM1237676, GEO:GSM1237701, GEO:GSM1250898, GEO:GSM1250899, GEO:GSM1250900, GEO:GSM1250901, GEO:GSM1374593, GEO:GSM1374594, GEO:GSM1669980, IARC_TP53:21648, IGRhCellID:KATOIII, IZSLER:BS TCL 151, JCRB:JCRB0611, JCRB:NIHS0052, KCB:KCB 2014045YJ, KCLB:30103, LiGeA:CCLE_710, LINCS_HMS:50022, LINCS_LDP:LCL-2003, NCBI_Iran:C640, PharmacDB:KATOIII_737_2019, PRIDE:PXD030304, Progenetix:CVCL_0371, PubChem_Cell_line:CVCL_0371, RCB:RCB2088, TKG:TKG 0213, Wikidata:Q54899539

ID: CVCL_0371

Hierarchy: cvcl_m882

Record Creation Time: 20220427T220657+0000

Record Last Update: 20260829T234402+0000

Ratings and Alerts

No rating or validation information has been found for KATO III.

Warning: Discontinued: JCRB; NIHS0052

Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Laurenziello P, et al. (2026) Salinomycin as a death switch: how gastric cancer cells choose their demise. *Cell death discovery*, 12(1).

Shen X, et al. (2026) A novel circSLIT2-encoded SLIT2 isoform suppresses neural invasion in gastric cancer. *Oncogene*, 45(31), 3181.

Kunnathattil M, et al. (2026) Chemical Profiling and ROS-Dependent Antiproliferative Activity of *Artemisia nilagirica* (C.B.Clarke) Pamp. (Asteraceae) Essential Oil in Human Gastric Adenocarcinoma Cells. *Chemistry & biodiversity*, 23(7), e71487.

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. *Molecular cancer therapeutics*, 25(5), 814.

Yu BM, et al. (2026) Yes-Associated Protein Drives *Helicobacter pylori*-Induced Metaplastic Changes in Gastric Epithelium. *Cellular and molecular gastroenterology and hepatology*, 20(9), 101814.

Zeng J, et al. (2026) KLF5 Activation Promotes Malignant Transformation to Drive Development of Lung Squamous Cell Carcinoma. *Cancer research*, 86(7), 1622.

Lu Y, et al. (2026) GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. *Cancer research*, 86(10), 2429.

Zhou Y, et al. (2025) Targeting PTBP3-Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(21), e2415983.

Cai G, et al. (2025) UMP functions as an endogenous regulator of NR4A1 to control gastric cancer progression. *Molecular cell*, 85(23), 4347.

Rinaldi R, et al. (2025) Biological Activity of Peptide Fraction Derived from *Hermetia illucens* L. (Diptera: Stratiomyidae) Larvae Haemolymph on Gastric Cancer Cells. *International journal of molecular sciences*, 26(5).

Xu Y, et al. (2025) WTX-L/??-arrestin2/LCN2 axis controls vulnerability to ferroptosis in gastric cancer. *iScience*, 28(3), 111964.

Mano Y, et al. (2025) DNA-hypermethylated human gastric cancer circumvents apoptosis in the absence of TP53 mutation. *The Journal of pathology*, 267(4), 435.

Wainer-Katsir K, et al. (2025) The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields). *Cell death discovery*, 11(1), 319.

Wirsik NM, et al. (2024) Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma. *Cancer medicine*, 13(7), e6866.

Sasahara M, et al. (2024) Therapeutic antibody targeting natriuretic peptide receptor 1 inhibits gastric cancer growth via BCL-2-mediated intrinsic apoptosis. *International journal of cancer*, 154(7), 1272.

Alva-Ruiz R, et al. (2024) YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. *FEBS open bio*, 14(11), 1873.

Hayashi K, et al. (2024) Cell-cell contact-dependent secretion of large-extracellular vesicles from EFN^Bhigh cancer cells accelerates peritoneal dissemination. *British journal of cancer*, 131(6), 982.

Thomas JD, et al. (2024) Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates. *Molecular cancer therapeutics*, 23(4), 541.

Hu C, et al. (2024) Proteome-based molecular subtyping and therapeutic target prediction in gastric cancer. *Molecular oncology*, 18(6), 1437.